SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

MANAGING ANEMIA IN HIV INFECTED INDIVIDUALS THROUGH ERYTHROPOIETIN THERAPY AND BLOOD TRANSFUSIONS

Ms. Nikita Kadam[1], Dr. Prachi Bansode[2], Dr. Vijaysinh Sable[3]
Dr. Rani Mhetre[4]
Author[1], Guide[2], Principal[3], Vice Principal[4]

ABSTRACT

Anemia is a common and complex complication that affects people who are infected with HIV/ AIDS, therefore thorough understanding of its processes and specialized care required. This study focuses anemia approaches are managing in HIV infected individuals through erythropoietin therapy EPO Therapy has surfaced and blood transfusions as a potentially effective treatment option for HIV as related anemia .This study also focuses on as it examines blood transfusions novel techniques and clinical issues for managing of HIV. This article anemia in the context summerizes existing information and and describes approaches for more management, from new successful anemia figuring out the complex interaction between HIV and anemia to weighing the advantages and disadvantages of erythropoietin Therapy and blood transfusions. The review discusses the difficulties in diagnosing patients, clinical recommen- dations and how anemia affects patient's quality of life. It als o explores novel iron stratergies , such as supplementation and erythropoietin emphasizing used to the context how they might be maximize erythropoiesis in OF HIV.

INTRODUCTION

Anemia is a common and clinically important consequence that affects the general well-being of people living with HIV and contributes to a multitude of health issues. Because of the important function that erythropoietin (EPO) plays in promoting the generation of red blood cells, EPO therapy has become a viable therapeutic option for treating anemia in this population Erythropoietin is a glycoprotein hormone that is mostly made by the kidneys and is essential in controlling erythropoiesis, the process that creates red blood cells. EPO is generated in reaction to hypoxia or decreased oxygen carrying capacity, which promotes the erythroid progenitor cells' maturation, differentiation, and proliferation in the bone marrow.1–16 Anemia is more common in people with HIV than in the general population, and its development is influenced by a variety of multifactorial etiologies. A number of intricate elements are involved in the pathophysiology of anemia in this situation, including direct virus impacts on bone marrow function, pharmaceutical side effects, and chronic inflammation. Because EPO therapy stimulates erythropoiesis, it offers a logical intervention in the management of HIV-related anemia. By treating the underlying red blood cell production. EPO has the potential to raise hemoglobin levels, reduce anemic symptoms, and maybe improve the general quality of life for HIV-positive people. This study focuses on blood transfusions as it examines novel techniques and clinical issues for managing anemia in the context of HIV. This article summarizes existing information and describes new approaches for more successful anemia management, from figuring out the complex interactions between HIV and anemia to weighing the advantages and disadvantages of blood transfusions. The review discusses the difficulties in diagnosing patients, clinical recommendations, and how anemia affects patients' quality of life. It also explores novel strategies, such as iron supplementation and erythropoiesis-stimulating drugs, emphasizing how they might be used to maximize erythropoiesis in the context of HIV. Patient-centered care is examined in relation to the difficulties surrounding blood transfusions, including immunomodulatory effects and infections contracted by transfusion. The study ends with a discussion of future directions and research needs, imagining a way forward for better outcomes and a higher standard of living for people with HIV and anemia[1].


- **Erythropoietin Therapy In HIV infected Persons :**

a.Physiological role of Erythropoietin:

The hormone erythropoietin (EPO), a glycoprotein mostly generated in the kidneys, is essential for controlling erythropoiesis, the process that creates red blood cells. Ensuring that tissues and organs receive enough oxygen is vital to EPO's physiological processes. The blood's oxygen content mostly controls the generation of EPO. The kidneys increase the production and release of EPO in response to lower oxygen availability, which can be caused by hypoxia or decreasing hemoglobin levels. This regulation is primarily mediated via the hypoxia-inducible factor (HIF) pathway, in which transcription and expression of EPO are triggered by

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

low oxygen levels stabilizing HIF. Target tissues are affected by erythropoietin, especially the bone marrow, which is home to erythroid progenitor cells and hematopoietic stem cells. EPO binds these cells' surface receptor (EPOR), starting a series of intracellular signaling processes. The survival, growth, and differentiation of erythroid progenitor cells depend on this interaction. EPO's main function is to promote erythropoiesis, which guarantees a steady flow of fully developed red blood cells. In the bone marrow, EPO stimulates committed erythroid progenitors and hematopoietic stem cells to differentiate into mature red blood cells. Numerous genes that govern the advancement of the cell cycle, survival, and hemoglobin synthesis are regulated throughout this phase. Because of its hypoxia sensitivity, EPO is an essential part of the body's low-oxygen adaptation processes.When conditions like anemia, high altitudes, or respiratory diseases are present, the increased production of EPO promotes the creation of red blood cells, which increases the blood's ability to carry oxygen[2].



The synthesis of EPO is precisely regulated to preserve equilibrium. The trigger for EPO production decreases when oxygen levels return to normal, resulting in a decline in EPO mixture. By means of this negative feedback loop, the body's oxygen requirements are taken into account when adjusting erythropoiesis.

b.Prevalence and Etiology of Anemia


Anemia is a common and complex problem that affects people with HIV/AIDS in many ways, having a major effect on both the course of the illness and quality of life. Anemia is more common in the HIV population than in the general population. Anemia may occur in between 30% and 95% of people living with HIV at some point during the course of their illness, according to estimates. This broad range is a result of the intricate interactions between a number of variables, such as the stage of HIV infection, the course of the illness, and the existence of comorbidities. HIV infection impairs erythropoiesis by directly affecting the bone marrow. The virus can impede the regular formation of red blood cells by infecting hematopoietic progenitor cells. Moreover, HIV-induced inflammatory cytokines are involved in the suppression of erythropoiesis.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Anemia may result from opportunistic infections, which are prevalent in people with severe HIV illness and weakened immune systems. Pathogens that affect erythropoiesis and worsen anemia include Mycobacterium avium complex, cytomegalovirus (CMV), and Mycobacterium tuberculosis.

c. Mechanisms underlying HIV Related Anemia

HIV-related anemia is a multifaceted hematological condition with several interrelated processes involved. Anemia in people with HIV develops and worsens as a result of interactions between the virus, immune system, and hematological processes. Pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ) are released when an HIV infection persists. Reduced formation of red blood cells results from elevated levels of these cytokines, which interfere with the regular regulatory pathways of erythropoiesis in the bone marrow. HIV targets the bone marrow, which is essential for the production of red blood cells. The virus can directly infect hematopoietic progenitor cells in the bone marrow, causing them to malfunction and lose their capacity to produce red blood cells. This direct effect on progenitors of erythroid cells helps to bone marrow suppression. Chronic immunological activation brought on by HIV infection results in the generation of cytotoxic T cells and antibodies. While trying to contain the virus, these immune reactions may unintentionally target and kill red blood cells, which can exacerbate hemolysis and anemia. Opportunistic infection circulating erythrocyte lifespan can be further reduced by immune-mediated hemolysis or direct infection of red blood cells by viruses like cytomegalovirus (CMV), which are frequently observed in advanced HIV disease[3].



Hepcidin is a crucial regulator of iron metabolism that is released in response to the production of inflammatory cytokines, especially IL-6. Increased hepcidin levels cause the gastrointestinal tract to absorb less iron and sequester it in macrophages, which impairs erythropoiesis and causes a functional iron shortage. Red blood cell life is decreased by hemolysis and chronic inflammation linked to HIV-related anemia. Relative iron deficit can result from the faster turnover of erythrocytes exceeding the reticuloendothelial system's capacity to recycle iron from senescent red blood cells. Some antiretroviral drugs, especially zidovudine, which is frequently prescribed in HIV therapy regimens, has the ability to inhibit bone marrow. Anemia may worsen as a result of the hematopoietic progenitor cells' toxicity, which may also reduce the formation of red blood cells.

d. Erythropoietin Therapy - Risk and Benefits

Treatment for anemia using erythropoietin (EPO) has been shown to be effective in a number of clinical settings, including HIV infection. However, EPO therapy has potential hazards as well as advantages, just like any medical intervention. As a hematopoietic growth factor, EPO encourages the bone marrow to produce red blood cells. Elevating hemoglobin levels to address the anemia linked to HIV infection is the main and expected benefit of EPO therapy. Raising hemoglobin levels may lessen anemia symptoms and improve the body's ability to carry oxygen. HIV patients may have a higher quality of life overall if EPO medication is able to reduce anemia-related symptoms such weakness, fatigue, and dyspnea. Relieving symptoms can improve mobility, daily functioning, and the capacity to participate in routine actions. Deep vein thrombosis and pulmonary embolism are two thromboembolic outcomes that are more

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

common in patients receiving EPO therapy. Increased blood viscosity from erythropoiesis stimulation can put people at risk for clot formation.

Raised hemoglobin levels brought on by EPO treatment could be a factor in hypertension and thicker blood. For those on EPO, controlling blood pressure becomes essential to reducing the risk of cardiovascular events. PRCA has been documented in patients receiving EPO, however it is uncommon; this is especially the case for those with chronic kidney disease. A significant decrease in red blood cell production is a hallmark of PRCA, which may require stopping EPO medication. Without appropriate iron supplementation and monitoring, people may be at danger of iron overload due to the increased iron usage that might result with EPO therapy. Overconsumption of iron can aggravate organ damage and oxidative stress. Neutralizing antibodies may form as a result of long-term EPO therapy, which would decrease the medication's effectiveness. This condition may lead to insufficient erythropoietic reaction and can need changing the dosage or stopping the medication. Each patient's risks and benefits from EPO therapy should be carefully considered, taking into account the patient's overall health status, underlying comorbidities, and the degree of their anemia. Maintaining strict vigilance and following protocols are necessary in order to mitigate such hazards[4].

e. Optimal Dosing Strategies

A comprehensive approach is necessary to determine the best dose techniques for erythropoietin (EPO) therapy in cases of HIV-related anemia, taking into account variables such the patient's unique characteristics, the severity of the anemia, and the disease stage. Start by carefully evaluating the initial hemoglobin levels. The degree of anemia should be taken into account while creating individualized treatment goals, along with other criteria like the patient's quality of life and the presence of symptoms. Assess the patient's general health status and take into account any comorbid conditions, such as cardiovascular disease or renal failure, as these may have an impact on the EPO dosage decision and help customize the treatment regimen to the patient's needs. Start EPO therapy at a low dose and increase it progressively in accordance with the patient's reaction. This strategy reduces the possibility of negative consequences, especially with relation to blood pressure and thromboembolic incidents. Establish a routine for tracking hemoglobin levels and clinical symptoms on a regular basis. To reach the intended hemoglobin target, adjust the EPO dosage appropriately, being careful not to increase it too much as this could lead to unfavorable outcomes.

Consider the patient's ART treatment in light of the possibility of hematologic adverse effects from some antiretroviral drugs, such as zidovudine. To achieve the best possible overall therapy results, modify the dosage of EPO in conjunction with other medication management. Examine the patient's iron level and, should an iron deficiency be shown, think about supplementing. Optimizing the erythropoietic response to EPO therapy requires adequate iron levels. Keep an eye on the patient's erythropoietic reaction to EPO treatment. Based on the rate at which hemoglobin increases and the achievement of target levels, modify the dosage. Individual differences in reaction can call for customized dose modifications. Take into account the patient's symptom response to EPO therapy, taking into account reductions in fatigue, dyspnea, and general wellbeing. Dosage modifications may be directed by the treatment's clinical outcome. Set your hemoglobin targets within the advised range to prevent overabundance increases that could raise the likelihood of unfavorable outcomes like thrombosis and hypertension. Achieving a balance between treating anemia and lowering hazards is the aim. In populations where cardiovascular issues already exist, proceed with caution since elevated hemoglobin levels may present a higher risk. Adjust dosage plans based on the patient's profile of cardiovascular risk. Evaluate the patient's response to EPO therapy on a regular basis and change the dosage as necessary. Long-term planning should include continuous monitoring and flexible dosage to account for evolving clinical state. If there is a poor response to EPO therapy or intolerance to it, look into other choices. These could include modifying the treatment plan, looking into possible causes, or looking into alternative therapies[5].

f. Clinical Outcomes of Erythropoietin Theray in HIV

The use of erythropoietin (EPO) therapy has been investigated as a possible intervention for the treatment of anemia in people infected with HIV. The increase in hemoglobin levels is one of the main therapeutic benefits of EPO therapy for HIV-related anemia. Research has indicated that erythropoiesis stimulation by EPO can successfully increase hemoglobin concentrations, hence improving oxygen-carrying capacity and treating underlying anemia. EPO therapy has demonstrated effectiveness in reducing anemia-related symptoms like weakness and fatigue. Higher hemoglobin levels are associated with higher energy levels, which may improve the overall quality of life for HIV-positive people. Exercise tolerance and dyspnea may both improve as a result of EPO therapy's clinical alleviation. People who receive treatment for the physiological effects of anemia may benefit from improved respiratory health and greater physical activity capability. Blood transfusion requirements have been linked to a decline in patients with HIV-related anemia who are receiving EPO therapy. EPO has the potential to lessen the need for exogenous blood products and the risks and issues that come with them by encouraging the body to produce red blood cells on its own.


SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Investigations into the possible effects of EPO therapy on the development of HIV illness are still ongoing. Although some data indicates a connection between anemia and faster HIV disease progression, more investigation is required to conclusively correlate EPO therapy to better hemoglobin levels and long-term HIV outcomes. When using EPO medication, close observation for thromboembolic events is essential. Healthcare professionals need to evaluate and control variables including high hemoglobin levels and underlying cardiovascular diseases that raise the risk of thrombosis. Active management of blood pressure is necessary due to the possibility of EPO-induced hypertension. Close monitoring is required. It could be necessary to use antihypertensive medications to reduce the cardiovascular risks linked to high hemoglobin levels. Sufficient iron supplementation and monitoring are crucial in preventing or treating iron overload or insufficiency. Improving iron status reduces related problems and enhances the effectiveness of EPO therapy. It is crucial to conduct long-term research investigating the long-term consequences of EPO therapy in HIV-related anemia. Research continues to be focused on understanding the long-term impacts on health outcomes, potential adaptations or side effects over extended periods of time, and the sustainability of hematological changes. Individual differences exist in the clinical results of EPO therapy for HIV-related anemia. Optimizing outcomes requires tailored treatment strategies that take into consideration several parameters, including pharmaceutical regimens, baseline health condition, and comorbidities, given the variability of patient groups[6].

- **Managing Anemia in HIV Infected Individuals Through Blood Transfusions**
  a. Blood Transfusion in HIV associated Anemia

  Interventions targeted at quickly raising low hemoglobin levels and enhancing general health are frequently required for the treatment of anemia in people with HIV. One of the most important therapeutic tools in the fight against severe anemia is blood transfusions. When hemoglobin levels drop below crucial thresholds in people with HIV-associated anemia, blood transfusions become necessary to treat symptoms like exhaustion, dyspnea, or reduced tissue oxygenation. The degree of anemia, the existence of symptomatic symptoms, and the underlying clinical setting all influence the choice to transfuse.75 Establishing the suitable threshold for transfusion is an essential clinical factor. Although particular cutoff points may differ, particularly when HIV is involved, standard standards comprise hemoglobin values of less than 7 to 8 g/dL for patients who are asymptomatic and greater cutoff points for with underlying cardiovascular disease or anemic symptoms. Customized evaluations are essential. Preventing transfusion responses requires that the receiver and donor blood be compatible. To lessen the risk of complications connected to transfusions, people with HIV may also want to consider utilizing leukoreduced blood products and choosing blood from donors who have similar HIV strains. Despite its effectiveness, blood transfusions have some hazards. People living with HIV may experience particular difficulties, such as heightened vulnerability to infections contracted through blood transfusions. To reduce these hazards and guarantee the general safety of the transfusion process, stringent screening procedures and adherence to safety guidelines are essential. It is still up for debate how blood transfusions might affect the course of HIV infection. Although transfusions do not in and of themselves speed up HIV replication, it is important to take into account the immunomodulatory effects of blood products as well as the possibility of immune-activating substances being introduced. Research on the overall effect on the course of HIV infection is still needed. Alternatives to blood transfusions may be taken into consideration in specific circumstances. Iron supplements and erythropoiesisstimulating agents (ESAs) are two examples of therapies that attempt to increase endogenous red blood cell synthesis[7].

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal



In the specific clinical situation, these alternatives must to be evaluated against the advantages and disadvantages of blood transfusions. Blood transfusions must to be smoothly included into the overall care of people living with HIV, including antiretroviral medication (ART) coordination. Overall treatment success is influenced by managing ART-related side effects, such as zidovudine-induced anemia, and improving HIV control. While receiving blood donations can instantly relieve severe anemia, a thorough long-term. A term management plan is necessary. Sustained control of anemia can be achieved by determining and treating underlying causes, optimizing antiretroviral medication, and taking cutting-edge measures such erythropoiesis-stimulating drugs.

b. Innovations in Anemia Management

Notable progress has been made in the management of anemia in people with HIV/AIDS, thanks to continued research and innovation that has made it possible to develop more focused and efficient interventions. ESAs are a game-changing breakthrough in the treatment of anemia because they increase red blood cell synthesis and decrease the requirement for blood transfusions. While some groups have found success with ESA use, its use in HIV-associated anemia must be carefully considered in light of the unique characteristics of each patient as well as any potential hazards, such as thrombosis. An essential component of managing anemia is treating iron deficiency. Novel formulations of iron supplements, like intravenous iron, have been developed. This is especially

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

helpful for HIV-positive persons who have trouble absorbing iron orally. Improving iron reserves helps to improve erythropoiesis and the results of treatment as a whole. Regenerative medicine has the potential to completely transform the treatment of anemia. Hematopoietic stem cell transplantation is one type of stem cell therapy that may be able to help people with HIV-associated anemia regain normal erythropoiesis. These novel techniques show promise for long-term anemia resolution, even if they are still in the early stages of investigation.

A more individualized strategy to managing anemia is now possible thanks to the development of precision medicine. Genetic disorders causing anemia may be corrected by genetic therapies, which include gene editing methods like CRISPR-Cas9. Curative and targeted treatments could be made possible by customizing interventions based on individual genetic profiles. New developments in antiretroviral therapy regimens help people with HIV-associated anemia achieve better results. Antiretroviral regimens can be tailored to reduce hematologic side effects, such as anemia caused by zidovudine, in order to achieve a more advantageous balance between managing anemia and HIV control.75 Given that anemia in the context of HIV is complex, combination treatments that target many facets of erythropoiesis and iron metabolism are now being investigated. Integrated techniques provide a comprehensive approach by integrating dietary support, emotional care, and pharmaceutical interventions for comprehensive anemia management.

Advances in the identification of biomarkers lead to a more sophisticated comprehension of the genesis and advancement of anemia. The precision of managing anemia can be improved by using biomarkers to guide actions and assess therapy response. This allows for rapid modifications to maximize outcomes. The combination of remote monitoring and telemedicine makes managing anemia easier to access and more patient-focused. Remote monitoring of symptomatology, medication adherence, and hemoglobin levels enables tailored treatment plan modifications and prompt intervention. Beyond merely using medical interventions, anemia management innovations also involve patient empowerment and community involvement. Peer support groups, digital health resources, and educational programs empower those living with HIV linked anemia to take an active role in their treatment, encouraging a cooperative and knowledgeable management style[8].

c. Challenges and considerations in Blood Transfusions

While blood transfusions are essential for treating severe anemia, including HIV-related cases, there are a number of obstacles and factors to take into account in order to guarantee the security and effectiveness of this therapeutic intervention. Transfusion-transmitted infections are a serious risk, particularly for people living with HIV. To reduce the risk of transmission, thorough screening for infectious diseases such as syphilis, HIV, and hepatitis B and C is crucial. Progress in screening technology is a contributing factor to the improvement of blood transfusion safety. Blood transfusions may influence the recipient's immunological response through immunomodulatory effects. Knowing the possible effects of transfusions on the course of HIV disease and the immune system as a whole is crucial in the setting of HIV, where immune function is already impaired. Care must be taken to weigh the advantages of transfusions against any possible immunomodulatory effects. One of the most important factors in minimizing transfusion reactions is making sure the recipient and donor blood are compatible. The variety of HIV strains might present extra complications for people living with the virus. To maximize the results of transfusions, crossmatching procedures and the selection of blood products from donors with compatible HIV strains become crucial factors.

Recurring transfusions carry the risk of alloimmunization, in which the recipient develops antibodies against donor blood antigens. People living with HIV may be particularly vulnerable to alloimmunization because of the virus's persistent inflammatory state. It is essential to keep an eye out for alloimmunization and its possible effects on next transfusions. Blood transfusion-related acute lung injury (TRALI) is an uncommon but serious side effect. In patients living with HIV, the underlying inflammatory condition may have an impact on the likelihood of TRALI. Identifying and treating TRALI with vigilance is crucial to maximizing patient safety. Iron excess can result with prolonged or recurrent blood transfusions, which is especially concerning for those with HIV who may already have problems with iron metabolism. Hemochromatosis-related problems can be avoided by controlling and monitoring iron levels, possibly with chelation therapy. Ethical and cultural issues are frequently raised by blood transfusions, and some people refuse to have transfusions due to personal or religious convictions. Addressing these issues in the context of HIV necessitates candid communication, deference to personal autonomy, and, when needed, alternate methods of managing anemia. Significant resources are needed for blood transfusions, including screening, crossmatching, and the availability of donor blood. Adherence to safety standards, appropriate screening procedures, and availability of safe blood products pose further barriers to the efficient administration of blood transfusions in settings with limited resources[9].

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

- **CONCLUSION**

Erythropoietin (EPO) therapy is a complex intervention with possible advantages and inherent hazards in the treatment of anemia in patients with Human Immunodeficiency Virus (HIV). This critical review has explored the physiological role of EPO, the prevalence and etiology of HIV-related anemia, the mechanisms underlying its development, and the clinical outcomes associated with EPO therapy. The intricate interplay between inflammatory cytokines, bone marrow suppression, red blood cell destruction, and disturbances in iron metabolism underscores the complexity of HIV-related anemia. Identifying these mechanisms informs targeted therapeutic approaches. The management of anemia in individuals with Human Immunodeficiency Virus (HIV) necessitates a comprehensive and patient-centered strategy. As we address the intricacies of this dual challenge, it is clear that progress in comprehending HIV-associated mechanisms of anemia, clinical factors, blood transfusions, and novel methodologies has markedly in the field of managing anemia. The necessity for focused therapy is highlighted by the HIV-related pathways that contribute to anemia. Healthcare professionals need to take into account the complex interactions between the virus and hematopoiesis when developing treatment strategies, as there are direct effects of the virus on erythropoiesis as well as immunomodulatory effects of chronic inflammation. Clinical factors are crucial in directing how anemia is diagnosed and treated. A thorough care plan must include an accurate diagnosis, a categorization of severity, and the identification of contributing factors. Optimizing outcomes requires striking a balance between the difficulties posed by opportunistic infections, antiretroviral medication, and unique patient features.

Blood transfusions serve as a fundamental intervention in the acute treatment of severe anemia. Nonetheless, issues such as transfusion-transmitted infections, immunomodulatory effects, and ethical considerations require a nuanced and patient-centered strategy. It is essential to comprehend the influence of blood transfusions on HIV disease progression and immune function to ensure the safety and efficacy of this intervention. Innovative strategies in anemia management, including erythropoiesis-stimulating agents, iron supplementation, and regenerative medicine, present promising opportunities for enhancing outcomes. The advancing field of precision medicine and genetic therapies offers potential for personalized and curative interventions, underscoring the ongoing commitment to improving care for individuals with HIV-associated anemia.

REFEREENCE

1. *Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):120-127.*
2. *Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University Journal of Medicine and Health Sciences. 2023;3(1):13-18. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93*
3. *Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University Journal of Medicine and Health Sciences. 2023;3(1):7-12. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91*
4. *Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023;6(2):141:1-2. Available from: https://www.researchgate.net/publication/368389735*
5. *Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV Status in Women of Reproductive Age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.*
6. *Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1):21-38. DOI: 10.22192/ijcrms.2017.03.01.004*
7. *Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2):1-5. DOI: 10.22192/ijcrms.2023.09.02.001*
8. *Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022;5(6):129. Available from: https://www.researchgate.net/publication/370636950*
9. *Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV-infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.*
10. *Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.*
11. *Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.*
12. *Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016;5:464-471. Available from: https://www.researchgate.net/publication/305489298*

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

13. *Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC Owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. Available from: https://www.academia.edu/download/38320140*
14. *Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state, Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10):55-65. DOI: 10.22192/ijarbs.2016.03.10.009*
15. *Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.*
16. *Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):110-119.*
17. *Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non-enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. J BioInnovation. 2016;5(1):24-30. Available from: https://www.researchgate.net/publication/301298774*
18. *Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022;5(6):130. Available from: https://www.researchgate.net/publication/370608799*
19. *Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015;3:139-144. Available from: https://www.academia.edu/download/38320159*
20. *Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices of HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. Available from: https://www.researchgate.net/publication/323664436*
21. *Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother-to-child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2):28-34. DOI: 10.22192/ijcrms.2017.03.02.005*
22. *Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.*
23. *Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023;6(1):139.*
24. *Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of new cases of human immunodeficiency virus: Pragmatic approaches of saving life in developing countries. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):128-134. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86*
25. *Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of activated partial thromboplastin time and prothrombin time in HIV and TB patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.*
26. *Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: Assessment in three levels of care in Cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.*
27. *Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022;5(8):137.*
28. *Obeagu EI, Obeagu GU. A review of knowledge, attitudes, and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142. DOI: 10.22192/ijarbs.2023.10.09.015*
29. *Obeagu EI, Onuoha EC. Tuberculosis among HIV patients: A review of prevalence and associated factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134. DOI: 10.22192/ijarbs.2023.10.09.014*
30. *Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104. DOI: 10.22192/ijcrms.2017.03.05.014*
31. *Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Vidya S, Kumar S. Distribution rate of chlamydial infection according to demographic factors among pregnant women attending clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.*
32. *Viola N, Kimono E, Nuruh N, Obeagu EI. Factors hindering elimination of mother-to-child transmission of HIV service uptake among HIV-positive women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14.*
33. *Okorie HM, Obeagu EI, Okpoli CH, Chukwu SN. Comparative study of enzyme-linked immunosorbent assay (ELISA) and rapid test screening methods on HIV, HBsAg, HCV, and syphilis among voluntary donors in Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183. DOI: 10.32474/JCCM.2020.02.000137*
34. *Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP, and AMP as an index of energy utilization and storage in HIV-infected individuals at NAUTH, Nigeria: A longitudinal, prospective, case-controlled study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.*
35. *Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors influencing early neonatal adverse outcomes among women with HIV with post-dated pregnancies delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211.*

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

36. *Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-demographic variables of people living with HIV/AIDS initiated on ART in 2014 at a tertiary health institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.*
37. *Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to antiretroviral therapy among HIV/AIDS patients in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.*
38. *Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the factors and predictors of adherence to healthcare of people living with HIV/AIDS in tertiary health institutions in Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75*
39. *Madekwe CC, Obeagu EI. Inequality of monitoring in human immunodeficiency virus, tuberculosis, and malaria: A review. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):6-15.*
40. *Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. Weights of infants born to HIV-infected mothers: A prospective cohort study in Federal Medical Centre, Owerri, Imo State. European Journal of Pharmaceutical and Medical Research. 2023;10(8):564-568.*
41. *Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. Biochemical alterations in adult HIV patients on antiretroviral therapy. World Journal of Pharmacy and Pharmaceutical Sciences. 2015;4(3):153-160.*
42. *Obeagu EI, Obeagu GU. Effect of CD4 counts on coagulation parameters among HIV-positive patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.*
43. *Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: A review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-48. DOI: 10.22192/ijcrcps.2019.06.12.004*
44. *Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in human immunodeficiency virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13. DOI: 10.22192/ijcrms.2023.09.02.002*
45. *Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.*
46. *Ifeanyi OE, Obeagu GU. The values of CD4 count among HIV-positive patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.*
47. *Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.*
48. *Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: Impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.*
49. *Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma associated with HIV/AIDS: A review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.*
50. *Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: The obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.*
51. *Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A retrospective study on human immunodeficiency virus among pregnant women attending antenatal clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research. 2018;1(2):08-14.*
52. *Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014;5:825-830.*
53. *Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV-positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology, and Pharma Research. 2014;3(1):186-189.*
54. *Obeagu EI. A review of challenges and coping strategies faced by HIV/AIDS discordant couples. Madonna University Journal of Medicine and Health Sciences. 2023;3(1):7-12.*
55. *Oloro OH, Obeagu EI. A systematic review on some coagulation profiles in HIV infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.*
56. *Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV-infected children in Umuahia, Abia State. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.*
57. *Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with sickle cell anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.*
58. *Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV seropositive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.*
59. *Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A review on blood-borne viral infections: Universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.*
60. *Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of some blood-borne viral infections and adherence to universal precautions among laboratory staff in Federal Teaching Hospital Abakaliki, Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).*

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

61. *Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.*
62. *Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV-infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.*
63. *Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49):e36599. DOI: 10.1097/MD.0000000000036599*
64. *Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State, Nigeria. Medicine (Baltimore). 2023;102(47):e36342. DOI: 10.1097/MD.0000000000036342*
65. *Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of dolutegravir regimen against other regimens on some hematological parameters, CD4 count, and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47):e35910. DOI: 10.1097/MD.0000000000035910*
66. *Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46):e36166. DOI: 10.1097/MD.0000000000036166*
67. *Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41):e35673. DOI: 10.1097/MD.0000000000035673*
68. *Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8):e1450. DOI: 10.1002/hsr2.1450*
69. *Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka Obi OR, Ugwu OP. Hematologic support in HIV patients: Blood transfusion strategies and immunological considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).*
70. *Obeagu EI, Ubosi NI, Uzoma G. Storms and struggles: Managing HIV amid natural disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.*
71. *Obeagu EI, Obeagu GU. Human immunodeficiency virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.*
72. *Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with sickle cell anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.*
73. *Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV infection rate in women: A catalyst to reducing HIV infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):1-6.*
74. *Fujiwara PI, Clevenbergh P, Dlodlo RA. Management of adults living with HIV/AIDS in low-income, high-burden settings, with special reference to persons with tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2005;9(9):946-958.*
75. *Martin R, Esper A, Martin GS. Hematologic complications. Non-Pulmonary Complications of Critical Care: A Clinical Guide. 2014:61-103.*
76. *Fischer D, Neb H, Choorapoikayil S, Zacharowski K, Meybohm P. Red blood cell transfusion and its alternatives in oncologic surgery – A critical evaluation. Critical Reviews in Oncology/Hematology. 2019;134:1-9.*
77. *Dodd RY. The risk of transfusion-transmitted infection. New England Journal of Medicine. 1992;327(6):419-421.*
78. *Wal P, Saed A, Almahtout AM, Ahmed SA. A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. Libyan Journal of Medical and Applied Sciences.*
79. *Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.*
80. *Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):120-127.*
81. *Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University Journal of Medicine and Health Sciences. 2023;3(1):13-18. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93*
82. *Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University Journal of Medicine and Health Sciences. 2023;3(1):7-12. Available from: https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91*
83. *Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV-positive women. J Pub Health Nutri. 2023;6(2):141:1-2.*
84. *Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.*
85. *Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(1):21-38. DOI: 10.22192/ijcrms.2017.03.01.004*
86. *Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2):1-5. DOI: 10.22192/ijcrms.2023.09.02.001*
87. *Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022;5(6):129.*

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

88. *Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV-infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.*
89. *Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.*
90. *Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.*
91. *Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical Centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.*
92. *Obeagu EI. Erythropoietin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.*
93. *Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: A review. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(3):10-18.*
94. *Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.*
95. *Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-84.*
96. *Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.*
97. *Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016;5(1):464-471.*
98. *Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non-enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. J BioInnovation. 2016;5(1):24-30.*